Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05442203 · ClinicalTrials.gov registry record · NA
Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease
A NA study of Atrial Fibrillation and Structural Heart Disease, sponsored by Tempus AI.
- Active
- Registry status
- NA
- Development phase
- 1,000
- Enrollment target
- 3
- Study locations
NCT05442203: Active NA study of Atrial Fibrillation and Structural Heart Disease, sponsored by Tempus AI.
NCT05442203 is a NA study of Atrial Fibrillation and Structural Heart Disease that is active but no longer recruiting, run by Tempus AI. The registered enrollment target is 1,000 participants, below the 2,992-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (67% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05442203, a NA study of Atrial Fibrillation and Structural Heart Disease, is active but no longer recruiting, sponsored by Tempus AI.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 1,000 participants
- Enrollment target
- 3
- Study locations
Study Summary
Atrial fibrillation is an abnormal beating of the heart that can lead to stroke or heart failure. Structural heart diseases are conditions that affect the heart valves or heart muscle and can cause permanent heart damage if left untreated. Sometimes people have atrial fibrillation or structural heart disease and do not know it. The purpose of this study is to evaluate two devices that can predict who has or may develop atrial fibrillation or structural heart disease based on the results of an electrocardiogram.
Conditions Studied
Interventions
- DEVICE Zio Patch Monitor
- DEVICE Echocardiogram
Study Locations (3)
Michigan
- Corewell Health - Grand Rapids
Ohio
- TriHealth - Cincinnati
Pennsylvania
- Geisinger Medical Center - Danville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2022-09-07 |
| Est. Completion | 2025-07 |
| Phase | NA |
What the registry record for NCT05442203 still lists
NCT05442203 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, below the 2,992-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (67% lower).
The record links to 2 conditions, with Atrial Fibrillation appearing as the primary indexed condition, and to 2 interventions - of which Zio Patch Monitor is the first listed.
NCT05442203 reports a single indexed study location in Michigan, Ohio, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05442203 about?
NCT05442203 is a clinical study titled "Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease". Atrial fibrillation is an abnormal beating of the heart that can lead to stroke or heart failure. Structural heart diseases are conditions that affect the heart valves or heart muscle and can cause permanent heart damage if left untreated. Sometimes people have atrial fibrillation or structural hear...
What is the current status of trial NCT05442203?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 1,000 participants. The study started on 2022-09-07. Estimated completion is 2025-07.
What conditions does trial NCT05442203 study?
This clinical trial studies the following conditions: Atrial Fibrillation, Structural Heart Disease.
What interventions are being tested in trial NCT05442203?
The interventions under investigation include: Zio Patch Monitor (DEVICE), Echocardiogram (DEVICE).
Who is sponsoring clinical trial NCT05442203?
This trial is sponsored by Tempus AI, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05442203 being conducted?
This trial has 3 study locations across Michigan, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05442203's enrollment target sits among peer trials
1,000 38th of 202 higher than 162 of 202 other Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Renal Denervation + PVI vs PVI Alone for Persistent AF
RECRUITING · NA
-
Pericardiotomy in Cardiac Surgery
RECRUITING · NA
-
CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation
RECRUITING · NA
-
The CONFORM Pivotal Trial
RECRUITING · NA
-
Vascular Closure With a Device Compared to Manual Compression After Atrial Fibrillation Ablation: The LockeT II Study
RECRUITING · NA
-
The Fourth Left Atrial Appendage Occlusion Study
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI